June 19, 2012
1 min read

Bipartisan agreement crucial to antibiotic research, development

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The United States House and Senate members have announced a bipartisan agreement on the FDA’s Safety and Innovation Act, which includes language to address antibiotic research and development and to bring new antibiotics to the country, according to an Infectious Disease Society of America statement.

IDSA has advocated for such antibiotic incentives, and hopes that the incentives spark interest in this area of medicine. Their 10 x ’20 initiative outlines the need to bring antibiotics to people who need them in the United States and abroad. They say that other incentives will be necessary to reach these goals.

Possible incentives include tax credits for research and development, public-private collaborations and the Limited Population Antibacterial Drug mechanism to streamline FDA approval, which the IDSA recently proposed.

“New, improved diagnostics are critically important for antibiotic development as well as for ensuring that antibiotics are used appropriately post-approval,” IDSA president Thomas G. Slama, MD, FIDSA, said in the statement. “IDSA will continue to work with other endorsers of the 10 x ’20 initiative to lead the charge for additional action.”